Q-omics provides the consensus-scored TCEA2 profile across patient tissues and cancer cell-line models. TCEA2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TCEA2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TCEA2 RNA expression shows 17,818 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, HNSC, and TGCT as cancer lineages where TCEA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEA2 survival associations across molecular data types. TCEA2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEA2 RNA expression–survival associations across cancer types. High TCEA2 expression shows unfavorable associations in MESO, STAD, LAML, ACC and LUAD, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for TCEA2 RNA expression.
This table summarizes TCEA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCEA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEA2 shows lower tumor expression in KICH, UCEC, LUAD and READ and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher TCEA2 RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with TCEA2 in patient tissues and cancer cell lines. In patient samples, TCEA2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
